

# Alessandra Bearz

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7669685/alessandra-bearz-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94  
papers

8,363  
citations

31  
h-index

91  
g-index

103  
ext. papers

9,800  
ext. citations

5  
avg, IF

4.75  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 94 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 239-46   | 21.7 | 3985      |
| 93 | Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 661-8   | 2.2  | 441       |
| 92 | Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2027-2039   | 59.2 | 427       |
| 91 | Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6865-72 | 2.2  | 394       |
| 90 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1654-1667  | 21.7 | 361       |
| 89 | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 874-886   | 21.7 | 314       |
| 88 | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1261-1273   | 21.7 | 266       |
| 87 | Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 1443-8  | 2.2  | 224       |
| 86 | Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 713-21   | 21.7 | 131       |
| 85 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , <b>2016</b> , 27, 417-23  | 19.3 | 101       |
| 84 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1357-1367                           | 8.9  | 100       |
| 83 | Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 51-6   | 8.7  | 93        |
| 82 | Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. <i>Lung Cancer</i> , <b>2010</b> , 68, 264-8   | 5.9  | 86        |
| 81 | Malignant peritoneal mesothelioma: a multicenter study on 81 cases. <i>Annals of Oncology</i> , <b>2010</b> , 21, 348-353  | 5.7  | 81        |
| 80 | Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. <i>Oncologist</i> , <b>2011</b> , 16, 1258-69  | 5.7  | 78        |
| 79 | An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 324-32                     | 7.5  | 70        |
| 78 | Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4663-9  | 2.2  | 70        |

|    |  |      |    |
|----|--|------|----|
| 77 | Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 1114-9  | 4    | 69 |
| 76 | Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , <b>2011</b> , 108, E250-7   | 5.6  | 67 |
| 75 | Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. <i>Lung Cancer</i> , <b>2014</b> , 83, 78-82  | 5.9  | 65 |
| 74 | Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 681-7   | 2.2  | 49 |
| 73 | Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1862-1866  | 8.9  | 48 |
| 72 | NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 799-811  | 21.7 | 44 |
| 71 | Solid pseudopapillary tumour of the pancreas. <i>Lancet Oncology</i> , <b>2003</b> , 4, 255-6  | 21.7 | 41 |
| 70 | Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , <b>2013</b> , 24, 2875-80  | 10.3 | 38 |
| 69 | Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1255-1265 | 8.9  | 36 |
| 68 | Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. <i>Lung Cancer</i> , <b>2011</b> , 72, 340-7   | 5.9  | 36 |
| 67 | Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 369-75   | 8.9  | 35 |
| 66 | Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 606-13                                     | 4    | 33 |
| 65 | Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 93-104  | 4.9  | 31 |
| 64 | Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. <i>BMC Research Notes</i> , <b>2012</b> , 5, 482  | 2.3  | 30 |
| 63 | Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. <i>Anti-Cancer Drugs</i> , <b>2013</b> , 24, 212-8  | 2.4  | 28 |
| 62 | Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study. <i>Onkologie</i> , <b>2009</b> , 32, 319-24  |      | 24 |
| 61 | Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. <i>BMC Cancer</i> , <b>2008</b> , 8, 216   | 4.8  | 22 |
| 60 | Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. <i>Lung Cancer</i> , <b>2008</b> , 60, 240-5  | 5.9  | 21 |

|    |  |      |    |
|----|--|------|----|
| 59 | Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. <i>European Urology Oncology</i> , <b>2019</b> , 2, 699-707                            | 6.7  | 19 |
| 58 | An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <i>Lung Cancer</i> , <b>2009</b> , 64, 199-206   | 5.9  | 19 |
| 57 | FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: a prospective study. <i>Archives of Gerontology and Geriatrics</i> , <b>2011</b> , 52, 89-93   | 4    | 18 |
| 56 | Staphylococcus cohnii septicaemia in a patient with colon cancer. <i>Journal of Medical Microbiology</i> , <b>2003</b> , 52, 101-102   | 3.2  | 16 |
| 55 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, e181-e182  | 8.9  | 15 |
| 54 | The role of diet in gastric cancer: still an open question. <i>Frontiers in Bioscience - Landmark</i> , <b>2012</b> , 17, 1640-8   | 2.8  | 15 |
| 53 | Malignant pericardial effusion: sclerotherapy or local chemotherapy?. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 734-5; author reply 736-7  | 8.7  | 15 |
| 52 | BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. <i>Lung Cancer</i> , <b>2016</b> , 95, 73-81                            | 5.9  | 14 |
| 51 | Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. <i>Current HIV Research</i> , <b>2010</b> , 8, 218-221                                   | 1.3  | 14 |
| 50 | Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. <i>Annals of Oncology</i> , <b>2021</b> , 32, 620-630                                | 10.3 | 14 |
| 49 | Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. <i>BMC Cancer</i> , <b>2013</b> , 13, 513                           | 4.8  | 13 |
| 48 | Interferon-alpha for maintenance of follicular lymphoma. <i>The Cochrane Library</i> , <b>2010</b> , CD004629  | 5.2  | 12 |
| 47 | Cancer in the elderly: the caregivers perception of senior patients informational needs. <i>Archives of Gerontology and Geriatrics</i> , <b>2009</b> , 49, e121-e125   | 4    | 10 |
| 46 | Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. <i>Onkologie</i> , <b>2008</b> , 31, 394-7   |      | 9  |
| 45 | Patient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives. <i>Journal of Cancer Education</i> , <b>2016</b> , 31, 405-12   | 1.8  | 8  |
| 44 | Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC). <i>Archives of Gerontology and Geriatrics</i> , <b>2012</b> , 55, 271-5   | 4    | 8  |
| 43 | Oxaliplatin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2013</b> , 13, 1344-53                           | 2.2  | 8  |
| 42 | Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). <i>Targeted Oncology</i> , <b>2015</b> , 10, 277-86 | 5    | 7  |

|    |  |      |   |
|----|--|------|---|
| 41 | Activity of crizotinib over choroidal metastases in non-small-cell lung cancer (NSCLC)-ALK rearranged: a case report. <i>BMC Research Notes</i> , <b>2014</b> , 7, 589   | 2.3  | 7 |
| 40 | Biomarkers in neuroendocrine tumors. <i>Frontiers in Bioscience - Scholar</i> , <b>2010</b> , 2, 332-42  | 2.4  | 7 |
| 39 | Target therapies in lung cancer. <i>Journal of Biomedicine and Biotechnology</i> , <b>2011</b> , 2011, 921231  |      | 7 |
| 38 | Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1176-7  | 10.3 | 7 |
| 37 | Dose finding of ifosfamide administered with a chronic two-week continuous infusion. <i>Oncology</i> , <b>2003</b> , 65 Suppl 2, 31-6  | 3.6  | 7 |
| 36 | Lymphangioliomyomatosis: A Case Report and Review of the Literature. <i>Tumori</i> , <b>2004</b> , 90, 528-531   | 1.7  | 7 |
| 35 | Comment on Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection <i>British Journal of Cancer</i> , <b>2012</b> , 106, 1899-900   | 8.7  | 6 |
| 34 | FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. <i>Cancer Investigation</i> , <b>2008</b> , 26, 610-4                               | 2.1  | 6 |
| 33 | Immune checkpoint inhibitors and response analysis: a tough challenge. A case report. <i>BMC Research Notes</i> , <b>2016</b> , 9, 349   | 2.3  | 6 |
| 32 | Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 1368-1376 | 4    | 6 |
| 31 | HIV-positive patients with liver metastases from colorectal cancer deserve the same therapeutic approach as the general population. <i>Onkologie</i> , <b>2010</b> , 33, 203-4   |      | 5 |
| 30 | Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1576  | 10.3 | 5 |
| 29 | Pharmacokinetic interaction between etoposide and tamoxifen in patients with hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , <b>1999</b> , 10, 815-9  | 2.4  | 5 |
| 28 | Unusual Presentation of Metastatic Hepatocellular Carcinoma in an HIV/HCV Coinfected Patient: Case Report and Review of the Literature. <i>Tumori</i> , <b>2008</b> , 94, 589-591  | 1.7  | 4 |
| 27 | Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , <b>2007</b> , 55, 125-7  | 5.9  | 4 |
| 26 | P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, S1184   | 8.9  | 3 |
| 25 | Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. <i>BJU International</i> , <b>2017</b> , 119, 846-853  | 5.6  | 3 |
| 24 | Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 353-361   | 3.6  | 3 |

|    |  |      |   |
|----|--|------|---|
| 23 | Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 405-409   | 2.8  | 3 |
| 22 | Small cell lung cancer in an elderly patient: efficacy of somatostatin analog treatment, a case report. <i>Onkologie</i> , <b>2011</b> , 34, 117-20  |      | 3 |
| 21 | Multidisciplinary approach in a HIV/HCV-positive patient with liver metastases by colorectal cancer in the HAART era. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1333-4   | 10.3 | 3 |
| 20 | FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1606-7  | 10.3 | 3 |
| 19 | Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. <i>Lung Cancer</i> , <b>2005</b> , 49, 417-8   | 5.9  | 3 |
| 18 | International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIa non-small-cell lung cancer. <i>Annals of Oncology</i> , <b>2021</b> | 10.3 | 3 |
| 17 | Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , <b>2021</b> , 26, 740-750  | 5.7  | 3 |
| 16 | Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 8945-8950  | 4.4  | 3 |
| 15 | First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL study. <i>Clinical Drug Investigation</i> , <b>2012</b> , 32, 755-60  | 3.2  | 2 |
| 14 | Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. <i>Oncotarget</i> , <b>2018</b> , 9, 15340-15349   | 3.3  | 2 |
| 13 | Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2019</b> , 14, 242-257  | 2.6  | 2 |
| 12 | Biomarkers in lung cancer. <i>Frontiers in Bioscience - Elite</i> , <b>2010</b> , 2, 1099-104  | 1.6  | 2 |
| 11 | Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, e31-e32  | 8.9  | 2 |
| 10 | Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report. <i>In Vivo</i> , <b>2021</b> , 35, 2941-2945   | 2.3  | 2 |
| 9  | Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1445   | 10.3 | 1 |
| 8  | Antiblastic treatment, for solid tumors, during pregnancy: a crucial decision. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2012</b> , 25, 1S-19S   | 3    | 1 |
| 7  | Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. <i>Cancer</i> , <b>2007</b> , 110, 2593-4; author reply 2594   | 6.4  | 1 |
| 6  | Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 5, v47-51   | 10.3 | 1 |

|   |   |      |   |
|---|---|------|---|
| 5 | Oxaliplatin-based chemotherapy in association with highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients. <i>Annals of Oncology</i> , <b>2006</b> , 17, 721-2  | 10.3 | 1 |
| 4 | Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. <i>Expert Review of Clinical Pharmacology</i> , <b>2021</b> , 14, 261-268 | 3.8  | 1 |
| 3 | Treatment of elderly patients affected by lung cancer: why to treat, when to treat and what we know. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2013</b> , 13, 1378-82   | 2.2  | 0 |
| 2 | Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1335-6   | 10.3 |   |
| 1 | Brigatinib as a treatment of ALK-positive non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2021</b> , 6, 299-305  | 1.6  |   |